Advertisement
Mergers and Acquisitions
Subscribe to Mergers and Acquisitions

The Lead

Daiichi Sankyo to Acquire Ambit Biosciences

September 29, 2014 10:15 am | News | Comments

Daiichi Sankyo Company and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis.

Chiltern Acquires Pacific Clinical Research

September 29, 2014 10:10 am | News | Comments

Chiltern has acquired Pacific Clinical Research, a pan-Asian CRO based in Singapore. The move...

Amag Pharma to Spend $675M on Lumara Health

September 29, 2014 10:03 am | News | Comments

The Waltham, Massachusetts, company said Monday it will spend $600 million in cash and another $...

M&A Update: Abbott, CFR, Pfizer, InnoPharma

September 26, 2014 11:07 am | News | Comments

Pfizer announced that it has completed its acquisition of pharmaceutical development company,...

View Sample

FREE Email Newsletter

Acorda Therapeutics to Acquire Civitas Therapeutics

September 24, 2014 8:05 am | News | Comments

Acorda Therapeutics has entered into an agreement to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525 million in cash. Acorda will obtain worldwide rights to CVT-301, a Phase 3 treatment candidate for OFF episodes of Parkinson’s disease (PD).

Pershing Capital Threatens to Sue Allergan if it Acquires Salix Without Vote

September 23, 2014 2:40 pm | by Ross Marowits, The Canadian Press | News | Comments

Allergan's largest shareholder, Pershing Square Capital, has threatened to sue the Botox maker if it attempts to buy Salix Pharmaceuticals without holding a shareholder vote. The investment fund headed by Bill Ackman has teamed up with Valeant Pharmaceuticals to make a $50-billion hostile takeover bid for Allergan.

Auxilium Pharma Rejects Endo's Takeover Offer

September 22, 2014 8:02 am | News | Comments

Auxilium, based in Chesterbrook, Pennsylvania, had adopted a one-year "poison pill" shareholder rights plan last week. The drugmaker continues to support its plan to combine with Canadian eye drugmaker QLT Inc. in an all-stock deal.    

Advertisement

Merck KGaA to Buy Sigma Aldrich for $17B

September 22, 2014 7:44 am | by David Mchugh - AP Business Writer - Associated Press | News | Comments

Merck says it has agreed to buy St. Louis-based chemical firm Sigma-Aldrich Corp. for $17 billion. Darmstadt-based Merck KGaA said Monday it is paying $140 per share in cash for all of Sigma-Aldrich's shares — a premium of 37 percent over Friday's closing price of $102.37.

PCI Acquires Biotec Services

September 19, 2014 8:21 am | News | Comments

The addition significantly expands PCI's presence in the UK/EU to support global investigational studies of medicinal products by adding packaging, storage and distribution capacity, as well as consultative services for clinical trial supplies. 

Auxilium Pharma Board Adopts Anti-Takeover Plan

September 17, 2014 8:48 am | by The Associated Press | News | Comments

The board of Auxilium Pharmaceuticals has adopted a "poison pill" shareholder rights plan to ward off a hostile takeover after Endo International PLC announced an unsolicited offer worth about $1.41 billion for its fellow drugmaker.   

Endo Makes $1.4B Offer for Auxilium Pharma

September 16, 2014 5:45 pm | by The Associated Press | News | Comments

Endo International PLC says it is making an unsolicited offer for Auxilium Pharmaceuticals that values Auxilium at $28.10 per share. The deal is worth $1.41 billion in cash and stock, based on Auxilium's shares outstanding. Endo values the offer at $2.2 billion.

Allergan Agrees to Move Forward with Meeting

September 16, 2014 6:44 am | by The Associated Press | News | Comments

Allergan and Pershing Square are agreeing on at least one step toward settling a fight over the makeup of the Botox-maker's board. Allergan will hold special shareholders meeting, as Pershing Square and its partner, Valeant Pharmaceuticals, continue their push for control of the drugmaker.

Advertisement

Mylan to Pay $300M for U.S. Rights to Arixtra Injection

September 10, 2014 7:59 am | News | Comments

Mylan has entered into an agreement to acquire the U.S. commercialization, marketing and intellectual property rights relating to Arixtra® (fondaparinux sodium) Injection and the authorized generic (AG) of Arixtra from Aspen Global Incorporated.

Merus Labs Acquire Sintrom from Novartis

September 8, 2014 8:49 am | News | Comments

Merus Labs International has acquired from Novartis AG, in certain European countries, the rights to manufacture, market, and sell the branded prescription medicine product Sintrom® (acenocoumarol).          

VNE Corporation Acquires HPT

September 4, 2014 2:46 pm | News | Comments

VNE Corporation, a member of the worldwide Ehrenberg Group has announced the acquisition of HPT (High Purity Technologies), effective August 26, 2014. HPT Inc. was founded in 1983 and currently supplies industries with electropolished and O2 cleaned tubes and fittings for ultra high purity distributions systems and related applications.

MAVERICK Acquires CQS Innovation

September 4, 2014 1:38 pm | News | Comments

MAVERICK, a supplier of industrial automation, enterprise integration and strategic manufacturing solutions, announced the acquisition of CQS Innovation, Inc., a Michigan-based systems integrator specializing in control and information systems for life sciences, chemical and metals industries.

PPD Acquires RCT Logic’s Exclusive License to Patented Clinical Trial Design Technology

September 3, 2014 10:44 am | News | Comments

PPD has acquired RCT Logic’s exclusive license from Massachusetts General Hospital for the portfolio of patents related to its sequential parallel comparison design (SPCD). SPCD is an alternative method for conducting well-controlled clinical trials that substantially decreases the impact on trial outcomes of any placebo effect.

Advertisement

Eisai Sells U.S. Rights to Zonegran Capsules to Concordia Pharmaceuticals

September 3, 2014 8:11 am | News | Comments

Eisai today announced it has entered into an agreement with Concordia Pharmaceuticals Inc., a subsidiary of Concordia Healthcare Corp., to purchase Eisai's U.S. and Puerto Rican commercialization and distribution rights to Zonegran.   

DPx Holdings B.V. Reaches Definitive Agreement to Acquire Gallus BioPharmaceuticals

August 28, 2014 11:55 am | News | Comments

DPx Holdings B.V., privately owned by JLL Partners and Royal DSM, has reached a definitive agreement to acquire all shares of Gallus BioPharmaceuticals, LLC, a contract manufacturing company specializing in biologics and current portfolio company of Ridgemont Equity Partners.

Novo Nordisk Buys Production Plant in New Hampshire

August 28, 2014 11:47 am | News | Comments

The facility was established in 1989, expanded in 2003-2006 and acquired by Olympus Biotech in 2011. It has been used primarily for mammalian cell manufacturing until production was phased out earlier this year.       

Cilag GmbH International Acquires Covagen AG

August 25, 2014 8:41 am | News | Comments

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb technology platform.

VIVUS Acquires Topiramate-Related Patents From Janssen Pharmaceuticals

August 25, 2014 8:29 am | News | Comments

VIVUS today announced the acquisition of a group of patents from Janssen Pharmaceuticals, Inc. covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions.   

Roche to Buy InterMune for $8.3B

August 25, 2014 8:10 am | News | Comments

Roche said Sunday it has reached an $8.3 billion deal to buy InterMune Inc., a California-based developer of treatments for lung diseases.                   

Allergan Reviews Meeting Requests in Takeover Bid

August 23, 2014 2:27 pm | by Linda A. Johnson - AP Business Writer - Associated Press | News | Comments

Allergan Inc. is reviewing shareholder requests for a special meeting to consider replacing most of its board, a change fellow drugmaker Valeant Pharmaceuticals International Inc. is seeking as part of the hostile takeover attempt it's been waging since April. Allergan has repeatedly...

Allergan Acquires LiRIS® Program from TARIS Biomedical®

August 14, 2014 8:43 am | News | Comments

Allergan has closed a transaction to acquire worldwide rights to TARIS Biomedical's® lead program, LiRIS®, which is currently in Phase 2 trials for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS).      

Valeant Pharmaceuticals Receives FTC Second Request Under Hart-Scott-Rodino

August 12, 2014 8:39 am | News | Comments

Valeant Pharmaceuticals International  announced that the company has received a request for additional information from the Federal Trade Commission in connection with Valeant's proposed acquisition of Allergan, Inc.      

Tekni-Plex to Acquire Closure Liner and Seal Manufacturer Tech-Seal

August 7, 2014 1:55 pm | News | Comments

Tekni-Plex, Inc. announced today that it has signed an agreement to acquire the assets of Tech-Seal Products, Inc. Tech-Seal manufactures closure liners and innerseals for food, pharmaceutical, cosmetic, and industrial applications.     

Takeda President: Company to Extend Global Reach Through Acquisitions

August 7, 2014 8:37 am | News | Comments

New Takeda Pharmaceutical Company President Christophe Weber said recently that Japan's biggest drugmaker will continue efforts to expand its business abroad through acquisitions and will outline a new strategy by the end of the year.   

Alvogen Acquires Korean Dream Pharma for $187M

August 6, 2014 8:22 am | News | Comments

Alvogen announced today that it has acquired Dream Pharma in South Korea for $187 million in cash. Dream will be acquired through Alvogen’s Asian subsidiaries and, on completion, will create one of the largest generic pharmaceutical companies in South Korea.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading